Home Newsfeeds SCworx Corp Will Issue $600,000 Worth Of Common Stock To Class Plaintiffs

SCworx Corp Will Issue $600,000 Worth Of Common Stock To Class Plaintiffs

-SEC Filing

byBenzinga Newsdesk

July 6, 2022

1 minute read

-SEC Filing

Sanofi Late-Breaking Amlitelimab Phase 2b Data Presented At EADV Show Potential Best-In-Class Profile In Atopic Dermatitis; Clinically Meaningful Improvements Were Seen In All Key Secondary Endpoints At Week 16 With Continued Improvements Through Week…

By Benzinga Newsdesk

October 13, 10:03 AM

Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitisPatients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and Severity

SNY

How To Earn $500 A Month From Nordson Stock Ahead Of Q2 Earnings

By Avi Kapoor

May 17, 8:42 AM

Nordson offers an annual dividend yield of 1.01%, which is a quarterly dividend amount of 68 cents per share ($2.72 a year).

NDSN

Events
News

MorphoSys Presented New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

By Charles Gross

December 11, 9:09 PM

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a type of bone marrow cancer with limited treatment options.

MOR

Bud Light Boycott Impact: King Of Beers Owner Dethroned As Top-Selling U.S. Beer Brand

By Chris Katje

June 14, 7:20 PM

A boycott that gained steam on social media and within certain political circles has had a large impact on the sale of a key product for a public company. Here’s a look at the impact of the Bud Light boycott and what’s happening to the U.S. beer market.

BUD

SCworx Corp Will Issue $600,000 Worth Of Common Stock To Class Plaintiffs

Related Posts

Sanofi Late-Breaking Amlitelimab Phase 2b Data Presented At EADV Show Potential Best-In-Class Profile In Atopic Dermatitis; Clinically Meaningful Improvements Were Seen In All Key Secondary Endpoints At Week 16 With Continued Improvements Through Week…

How To Earn $500 A Month From Nordson Stock Ahead Of Q2 Earnings

MorphoSys Presented New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

Bud Light Boycott Impact: King Of Beers Owner Dethroned As Top-Selling U.S. Beer Brand